$1.03
0.0353.52%
Last update: Nov 10, 3:48 AM
Cardiol Therapeutics Inc
CRDLNASDAQ
Cardiol Therapeutics fell 1.9% from $1.05 to $1.03, behind the S&P 500's +10.5%. Its worst day was Sep 10 (−13.3%), and its low came Mar 20 at $0.93.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.09 beat the $-0.09 estimate on $0.00 revenue.
0.0% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute
−10.1% · S&P 500 +0.1%
Cardiol Therapeutics shares rose 10.1%, while the S&P 500 fell 0.1%.
+10.1% · S&P 500 −0.1%
Cardiol Therapeutics closed at its lowest level of the year, 11.8% below where the year started.
−2.2% · S&P 500 −1.4%
EPS of $-0.05 beat the $-0.09 estimate on $0.00 revenue.
+3.7% · S&P 500 +0.8%
Cardiol Therapeutics shares fell 9.9%, while the S&P 500 fell 0.4%.
−9.9% · S&P 500 −0.4%
EPS of $-0.07 beat the $-0.07 estimate on $0.00 revenue.
+1.1% · S&P 500 −0.2%
Cardiol Therapeutics shares rose 10.8%, while the S&P 500 fell 0.5%.
+10.8% · S&P 500 −0.5%
EPS of $-0.04 beat the $-0.09 estimate on $0.00 revenue.
+12.5% · S&P 500 +0.7%
Cardiol Therapeutics closed at its highest level of the year, 117.6% above where the year started.
+2.9% · S&P 500 −0.5%
Where it ended: a close of $1.03 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.06).
Nothing in the past 12 months.
All CRDL dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CRDL and SPY from Benzinga historical bars. Not investment advice.
